Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25865447 | 0.86 | HSD17B10 (0.39) | HSD17B10NPC1GRIN1GRIN2BALDH1A1 | |
| SCHEMBL25865334 | 0.82 | NPC1 (0.58) | HSD17B10NPC1KDM4EALDH1A1MIF | |
| SCHEMBL25865370 | 0.80 | HSD17B10 (0.45) | HSD17B10NPC1KDM4EALDH1A1PDE4B | |
| SCHEMBL25865316 | 0.77 | HSD17B10 (0.40) | HSD17B10NPC1 | |
| SCHEMBL16361870 | 0.71 | HSD17B10 (0.57) | HSD17B10ALDH1A1PDE4B | |
| SCHEMBL31682602 | 0.71 | HSD17B10 (0.57) | HSD17B10ALDH1A1PDE4B | |
| SCHEMBL25865429 | 0.68 | HSD17B10 (0.45) | HSD17B10PDE4B | |
| SCHEMBL20874692 | 0.68 | GALR3 (0.40) | HSD17B10NPC1GRIN1GRIN2BALDH1A1 | |
| SCHEMBL25446762 | 0.65 | CNR2 (0.46) | HSD17B10GRIN1GRIN2BALDH1A1 | |
| SCHEMBL30187097 | 0.65 | CNR2 (0.46) | HSD17B10GRIN1GRIN2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | HSD17B10 715/4885NPC1 218/4885GRIN1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.